Improving Safety and Efficiency of Oral Chemotherapy Administration With Cynthia Huff, DNP, RN

At the recent 47th Oncology Nursing Society (ONS) Congress in Anaheim, California, Cynthia Huff, DNP, RN, MSN, OCN®, CRNI, CNL®, Manager of the Ambulatory Infusion Center at Long Beach Medical Center, presented two posters about the importance of safe oral chemotherapy administration and the need to ensure proper lab monitoring and follow-up for patients receiving chemotherapy. Afterwards, she spoke with Oncology Data Advisor to further expound on her work in these areas and her passion for guar...

Continue reading

CARG Chemotherapy Toxicity Calculator Found Not Valid for Older Patients With Hematologic Malignancies: Ashley Rosko, MD

Understanding the balance between effective treatments and health-related quality of life is crucial, especially when treating older adults with hematologic malignancies. The Cancer and Aging Research Group (CARG) chemotherapy toxicity calculator has been sufficiently studied and utilized in patients with solid tumors; however, its efficacy in the hematologic malignancy setting was previously unknown. In a study recently presented at the American Society of Hematology (ASH) 63rd Annual Meeting &...

Continue reading

FDA Approves Pembrolizumab Combination for Cervical Cancer

The FDA has granted approval to pembrolizumab (Keytruda®, Merck) in combination with chemotherapy, with or without bevacizumab, for patients with persistent, recurrent, or metastatic cervical cancer whose tumors express programmed death-ligand 1 (PD-L1). The FDA has also granted regular approval to single-agent pembrolizumab for patients with recurrent or metastatic cervical cancer whose tumors express PD-L1, with a combined positive score of ≥1, who experienced disease progression on or after c...

Continue reading

Atezolizumab Indication Withdrawn from Triple-Negative Breast Cancer Treatment

In consultation with the FDA, the accelerated approval of atezolizumab (Tecentriq®, Genentech) in combination with nab-paclitaxel has been voluntarily withdrawn from the treatment of patients with programmed death ligand 1 (PD-L1)–positive unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). "Triple-negative breast cancer is a heterogenous disease entity with a high unmet medical need," wrote David Miles, MD, Lead Clinician for Breast Cancer at Mount Vernon Cancer Ce...

Continue reading

Improving the Management of Metastatic Breast Cancer: A Conversation With Dr. Sara Tolaney

Keira Smith: Hi, I'm Keira Smith from Oncology Data AdvisorTM. I'm here today with Dr. Sara Tolaney. Sara Tolaney, MD, MPH: Thanks so much for having me. I'm Sara Tolaney. I'm a breast medical oncologist at Dana-Farber Cancer Institute here in Boston. Keira Smith: Thank you so much for joining us, Dr. Tolaney. So what are some of the most challenging aspects of managing patients with metastatic breast cancer? Dr. Tolaney: I think we've made incredible progress for our patients with metastatic br...

Continue reading

FDA Issues Survival Alert for Melphalan Flufenamide in Multiple Myeloma Treatment

The FDA has issued an alert that melphalan flufenamide (Pepaxto®, Oncopeptides AB) in combination with dexamethasone has demonstrated an increased risk of death in the OCEAN trial (NCT03151811) of patients with multiple myeloma. Melphalan flufenamide plus dexamethasone was granted accelerated approval in February 2021 for patients with relapsed/refractory multiple myeloma who have been treated with at least four prior lines of therapy and whose disease is refractory to at least one proteasome in...

Continue reading

FDA Approves Daratumumab and Hyaluronidase-Fihj With Chemo and Steroid for Multiple Myeloma

The FDA has granted approval to daratumumab and hyaluronidase-fihj (Darzalex Faspro®, Janssen Biotech, Inc.) in combination with pomalidomide and dexamethasone for patients with multiple myeloma who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor. "In a phase 1b study, intravenous daratumumab plus pomalidomide and dexamethasone induced a very good partial response," wrote Meletios A. Dimopoulos, MD, Professor and Chairman of the Department of C...

Continue reading

Triple-Negative Breast Cancer: Which is Better, Adjuvant Chemotherapy or Radiotherapy?

In patients who have been diagnosed with T1 N0 M0 triple-negative breast cancer (TNBC), age plays a role in whether chemotherapy or radiotherapy will lead to better outcomes for overall survival and breast cancer–specific survival (BCSS), according to the results of a cohort study now published in JAMA Network Open. The investigators, led by Zhen Zhai, MD, of the Department of Breast Surgery in the First Affiliated Hospital in the College of Medicine at Zhejiang University in Hangzhou, China, en...

Continue reading

CTC Count-Driven Treatment Improves Survival in HR-Positive, HER2-Negative Metastatic Breast Cancer

Using circulating tumor cell (CTC) count to determine whether chemotherapy or endocrine therapy is used improves survival outcomes compared with clinically determined treatment in patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer, according to the results of the open-label, randomized phase 3 STIC CTC trial published today in JAMA Oncology. The investigators, led by François-Clément Bidard, MD, PhD, Professor of Medicine at the University of Paris-Sac...

Continue reading

Modern Radiation Therapy Doses for Early-Stage Hodgkin Lymphoma: Chelsea Pinnix, MD, PhD

While radiation therapy is an effective treatment for patients with early-stage favorable Hodgkin lymphoma, it also poses a risk of long-term toxicity to the surrounding organs and tissue. In a study recently published in JAMA Network Open, a team of researchers led by first author Chelsea Pinnix, MD, PhD, of MD Anderson Cancer Center, found that combined modality therapy consisting of ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) and contemporary radiation therapy (RT) demonstrated effic...

Continue reading

Modern Radiation Plus Chemo Effective and Safe for Early-Stage Hodgkin Lymphoma

According to the results of a new study, combined modality therapy consisting of ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) followed by contemporary radiation therapy (RT) was effective and safe in patients with early-stage favorable Hodgkin lymphoma, with low radiation doses delivered to at-risk organs. "While maximal efficacy is demonstrated with combined modality therapy, RT is often omitted in fear of late adverse effects," write the investigators, led by first author Chelsea C. Pi...

Continue reading

Breast Cancer in Older Patients With Comorbidities: Chemotherapy Improves Survival

In older patients with multiple comorbidities and estrogen receptor (ER)-positive, node-positive breast cancer, chemotherapy improves survival, according to a study published today in JAMA Oncology. "Breast cancer risk and the incidence of comorbidities increase with age. Treatment of elderly patients with significant comorbidities is challenging," write the investigators, led by first author Nina Tamirisa, MD, Assistant Professor of Breast Surgical Oncology at The University of Texas MD Anderso...

Continue reading

Preventing Venous Thromboembolism: Apixaban More Effective With Solid Tumors

A preplanned post-hoc analysis of the AVERT trial, a randomized, placebo-controlled, double-blind clinical trial of apixaban for the prevention of venous thromboembolism (VTE), reveals that among ambulatory patients with cancer initiating chemotherapy, characteristics of both the patient and the cancer in question impact the efficacy of apixaban for VTE prophylaxis. "Patients with active cancer have an increased risk of venous thromboembolism (VTE) complications which is associated with morbidit...

Continue reading

Appendix Cancer Model Predicts Efficacy of Chemotherapy

Because appendix cancer is rare, with only 1,000 people diagnosed in the United States every year, it is not as well understood as more common tumor types. That might change with the development of a patient-specific organoid model of the appendix which allows physicians to predict the efficacy of chemotherapy treatments prior to beginning them. Since every patient responds differently to treatment, this model, created by scientists at the Wake Forest Institute for Regenerative Medicine (WFIRM) ...

Continue reading

“Sponge” Absorbs Excess Chemo Drugs to Avoid Side Effects

Chemotherapy can be highly effective at treating cancer, but doctors often cannot prescribe the optimal cancer-killing dose due to systemic toxic side effects. When chemotherapy is administered to a cancerous organ via intra-arterial infusion, 50% to 80% of the drug generally does not remain in that organ. The excess passes on to the veins that drain the organ, entering the circulatory system, where it gets distributed to the rest of the body. Researchers from the University of California, Berke...

Continue reading

Breast Cancer: BRCA1/2 Mutations Enhance Chemotherapy’s Efficacy

Carriers of germline variants in the BRCA1 and BRCA2 genes are more likely to experience a pathologic complete response to two different chemotherapy regimens, according to a retrospective study now published in JAMA Oncology. This study was a secondary analysis of data from the GeparOcto multicenter prospective clinical trial, in which 945 women with different subtypes of high-risk, early-stage breast cancer were randomized to receive either sequential intense dose-dense epirubicin/paclitaxel/c...

Continue reading

Preventing Premature Menopause in Breast Cancer Chemotherapy

Chemotherapy can cure early-stage breast cancer, but it can also result in premature menopause, a highly unwelcome long-term side effect. In the final results of its investigation, the Southwest Oncology Group (SWOG)'s Prevention of Early Menopause Study (POEMS) reports a potential solution: women who receive goserelin (Zoladex®, AstraZeneca) along with standard chemotherapy for hormone-receptor negative breast cancer increase their chances of becoming pregnant without negatively impacting ...

Continue reading

PTUPB: A Key to Hindering Tumor Inflammation

Although chemotherapy is a potent treatment, it sometimes causes dying cancer cells to become inflamed, triggering the growth of more malignant cells. Researchers have discovered a new anti-inflammatory compound that decreases tumor inflammation and reduces cancer growth in ovarian tumors in mice. In these recent developments, published in Proceedings of the National Academy of Sciences, investigators discovered that first-line platinum- and taxane-based chemotherapies fuel a macrophage-derived ...

Continue reading

Testicular Cancer: Half the Chemotherapy, Same Efficacy

​One cycle of chemotherapy with bleomycin, etoposide, and cisplatin (BEP) works just as well as two cycles for the adjuvant treatment of high-risk, stage 1 nonseminomatous or combined germ cell tumors of the testis, report the investigators of a single-arm phase 3 study. Patients with testicular cancer, the most common cancer among American males between the ages of 15 and 35, often present with stage 1 disease. However, many nonseminomas and combined germ cell tumors of the testis have malignan...

Continue reading

Olanzapine 5 mg Effective for Preventing CINV

In order to prevent chemotherapy-induced nausea and vomiting (CINV), 10 mg of olanzapine, an antipsychotic, is often added to standard antiemetic therapy including aprepitant, palonosetron, and dexamethasone. However, reducing the dose of olanzapine to 5 mg is recommended by guidelines to mitigate sedation, a common side effect of olanzapine. In this randomized, double-blind, placebo-controlled, phase 3 trial, researchers discovered that 5 mg of olanzapine is effective at treating CINV in patien...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.